Wegovy HD: What Is the New High-Dose Wegovy 7.2 mg?
✓ Free to download
Wegovy HD (semaglutide 7.2 mg) was FDA approved on March 19, 2026. Here is what it is, who it is for, and how it differs from standard Wegovy.
Wegovy HD received FDA approval on March 19, 2026. It is a higher dose of the same semaglutide injection that has been available since 2021, at 7.2 mg rather than the standard 2.4 mg maintenance dose. The 7.2 mg dose is also approved for adults with obesity in the EU and UK.
For patients who have been on Wegovy and want to understand what this new dose means — and whether it could be right for them — here is a complete overview.
What is Wegovy HD?
Wegovy HD contains semaglutide 7.2 mg in a 0.75 mL single-dose pen and is administered as a once-weekly subcutaneous injection, the same delivery method as standard Wegovy. The molecule and the mechanism are identical to existing Wegovy. The difference is the dose.
Semaglutide works by activating GLP-1 receptors in the brain and gut, reducing appetite, slowing gastric emptying, and improving blood sugar regulation. The additional weight loss seen with Wegovy HD is thought to reflect a stronger effect on appetite at the higher dose.
Complete semaglutide dose ladder (Wegovy line):
| Dose | Phase |
|---|---|
| 0.25 mg | Starting dose (weeks 1–4) |
| 0.5 mg | Escalation (weeks 5–8) |
| 1 mg | Escalation (weeks 9–12) |
| 1.7 mg | Escalation (weeks 13–16) |
| 2.4 mg | Standard maintenance dose (from week 17) |
| 7.2 mg | Maximum dose — only after at least 4 weeks on 2.4 mg, if your doctor decides more weight loss is needed |
The 7.2 mg dose is not a starting point. Under the US label, it is the top of the ladder for adults who have tolerated 2.4 mg for at least 4 weeks and need additional weight loss. The label moves directly from 2.4 mg to 7.2 mg, with no intermediate dose.
Why does a higher dose produce more weight loss?
Tripling the dose does not triple the weight loss. In STEP UP, 7.2 mg produced about 3 percentage points more average weight loss than 2.4 mg.
At 2.4 mg, semaglutide suppresses appetite and reduces caloric intake. At 7.2 mg — three times the standard maintenance dose — blood levels of semaglutide are higher, and the appetite-reducing effect is thought to be stronger for many people. Appetite reduction is considered the main driver of weight loss with GLP-1 medicines.
What weight loss does Wegovy HD produce?
In the 72-week STEP UP trial in 1,407 adults with obesity without diabetes, people taking 7.2 mg lost an average of 20.7% of body weight if they stayed on treatment, or 18.7% counting everyone regardless of whether they stopped. About one in three (31.2%) lost 25% or more. In STEP UP T2D, in adults with obesity and type 2 diabetes, average weight loss with 7.2 mg was 13.2% (14.1% among people who stayed on treatment).
For comparison (separate trials, so not directly comparable):
| Drug and dose | Average weight loss (counting everyone) |
|---|---|
| Wegovy 2.4 mg (STEP 1, 68 weeks) | 14.9% |
| Wegovy 2.4 mg (STEP UP, 72 weeks) | 15.6% |
| Wegovy HD 7.2 mg (STEP UP, 72 weeks) | 18.7% (20.7% if staying on treatment) |
| Zepbound 15 mg (SURMOUNT-1, 72 weeks) | 20.9% |
In STEP UP, 7.2 mg produced about 3 percentage points more average weight loss than 2.4 mg. For someone at 100 kg, that is roughly 3 kg more on average, though individual results vary widely.
The one-in-three figure for 25%+ weight loss is notable, but the STEP UP trial did not compare Wegovy HD with tirzepatide or surgery.
Who is Wegovy HD for?
Wegovy HD is not a first-line option and it is not for everyone on Wegovy. Under the US label, it is for adults who:
- Have obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with a weight-related health condition
- Have tolerated Wegovy 2.4 mg for at least 4 weeks
- Need additional weight loss, as judged by their doctor
- Are under ongoing medical supervision
It is not approved for adolescents.
Your prescribing doctor will determine whether Wegovy HD is appropriate for your situation based on your full medical history, current response to treatment, and tolerance of semaglutide side effects.
Do not self-escalate. The jump from 2.4 mg to 7.2 mg is significant and needs a new prescription and medical supervision to manage side effects at the higher dose. Never combine pens or take extra doses to reach 7.2 mg.
How does Wegovy HD differ from CagriSema or Retatrutide?
Wegovy HD is an established molecule at a higher dose. It is not a new drug with a new mechanism.
For context, here is where it sits in the current pipeline landscape:
| Drug | Mechanism | Status (October 2026) | Avg. weight loss in trials |
|---|---|---|---|
| Wegovy 2.4 mg | GLP-1 agonist | ✅ Approved | ~15% |
| Zepbound 15 mg | GLP-1 + GIP | ✅ Approved (US) | ~21% |
| Wegovy HD 7.2 mg | GLP-1 agonist (higher dose) | ✅ FDA approved (March 2026) | ~19–21% |
| CagriSema | GLP-1 + amylin (cagrilintide) | Under FDA review, not approved | ~20–23% |
| Retatrutide | GLP-1 + GIP + glucagon | Phase 3, not approved | Varies by trial |
Drugs like CagriSema and retatrutide use different mechanisms and have shown large average weight loss in trials, but as of October 2026 neither is approved. Trial results come from different studies and are not directly comparable. Products sold online under those names are not legitimate.
For patients who need more than 2.4 mg of semaglutide can deliver, Wegovy HD adds an approved option.
What are the side effects of Wegovy HD?
Side effects for Wegovy HD are consistent with the existing semaglutide class:
- Nausea (most common, especially early in escalation)
- Diarrhoea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Reflux or heartburn
- Altered skin sensation (dysaesthesia), such as tingling, burning, pain or sensitivity of the skin: reported by 22.9% on 7.2 mg in STEP UP versus 6.0% on 2.4 mg; it usually resolved on its own or with a dose reduction
In STEP UP, gastrointestinal side effects were more common with 7.2 mg (70.8%) than 2.4 mg (61.2%). Hair loss was also reported more often at the higher dose. If side effects are hard to manage, your doctor may consider returning to a lower dose.
Patients who struggled with side effects on standard Wegovy should discuss their history carefully with their doctor before considering Wegovy HD. The higher dose amplifies both the benefits and the potential for GI symptoms.
When to seek medical attention
Get urgent medical help if you experience:
- Severe and persistent abdominal pain, which may spread to your back (possible pancreatitis)
- Pain in the upper right abdomen, fever, or yellowing of skin or eyes (possible gallbladder issues)
- Signs of a serious allergic reaction: swelling of the face, lips or throat, difficulty breathing
- Vomiting or diarrhoea so severe you cannot keep fluids down (risk of dehydration and kidney injury)
Also tell your doctor if you take insulin or a sulfonylurea (risk of low blood sugar), if you have diabetic eye disease and notice vision changes, if you are pregnant or planning a pregnancy, or before any surgery or sedation. Wegovy carries a US boxed warning about thyroid C-cell tumours and must not be used if you or a close relative has had medullary thyroid carcinoma (MTC) or if you have MEN 2.
Availability and cost
At approval, Novo Nordisk said it expected to launch Wegovy HD in the US as a single-dose pen in April 2026. Check with your pharmacy for current availability. In the EU and UK, the 7.2 mg dose is approved, with decisions on a single-dose pen expected in the second half of 2026.
Insurance coverage for Wegovy HD may differ from standard Wegovy, so check with your plan. In February 2026, Novo Nordisk said it would cut US list prices of Ozempic and Wegovy to $675 a month from January 1, 2027; reports did not say whether this includes Wegovy HD. Novo Nordisk also offers self-pay pricing through NovoCare Pharmacy; check current prices.
How to track Wegovy HD
If you switch to the higher dose, your weekly pattern will shift. Appetite suppression, side effect timing, and energy levels may all change compared to your previous dose.
Keeping a consistent log through the transition makes it much easier to tell whether the new dose is settling in or whether something needs adjusting. What to track specifically:
- When side effects appear relative to injection day
- How appetite control compares to previous doses: stronger, weaker, or about the same
- Whether the weekly end-of-cycle hunger pattern shifts
- Weight trend week by week, not day by day
Weight Easy tracks dose changes, weekly injection logs, symptom patterns, and weight trends in one place — useful when you are moving between dose tiers.
Final takeaway
Wegovy HD is the same weekly semaglutide medicine at a higher dose (7.2 mg), FDA approved in March 2026. In STEP UP it produced more average weight loss than the standard 2.4 mg dose (18.7% versus 15.6% counting everyone; 20.7% for 7.2 mg among people who stayed on treatment), with more digestive side effects and altered skin sensation.
It is not a starting medication. It is an option for adults who have tolerated 2.4 mg for at least 4 weeks, need additional weight loss and are medically supervised.
Talk to your doctor about whether Wegovy HD is appropriate for your situation.
Consult your healthcare provider before starting, adjusting, or stopping any medication.
Sources
- Wegovy US prescribing information (Novo Nordisk, revised June 2026): https://www.novo-pi.com/wegovy.pdf
- FDA announcement of higher-dose semaglutide (Wegovy HD) approval, 19 March 2026: https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide
- Novo Nordisk release: Wegovy HD (semaglutide 7.2 mg) approved in the US, 19 March 2026: https://www.biospace.com/press-releases/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss
- Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13:949-963: https://pubmed.ncbi.nlm.nih.gov/40961952/
- Lingvay I et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D). Lancet Diabetes Endocrinol. 2025;13:935-948: https://pubmed.ncbi.nlm.nih.gov/40961953/
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002: https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022: https://pubmed.ncbi.nlm.nih.gov/35658024/
- Zepbound US prescribing information (Eli Lilly, revised August 2026): https://pi.lilly.com/us/zepbound-uspi.pdf
- Novo Nordisk to cut US list prices of Ozempic and Wegovy to $675 a month from 1 January 2027 (FOX6/AP, 25 February 2026): https://www.fox6now.com/news/novo-nordisk-slash-list-prices-ozempic-wegovy-up-50
Related Articles
FAQ
What is Wegovy HD?
Wegovy HD is a higher-dose version of the injectable semaglutide weight loss drug, containing 7.2 mg per dose compared to the standard 2.4 mg. It was FDA approved on March 19, 2026. The 7.2 mg dose is also approved for adults with obesity in the EU and UK.
Who is Wegovy HD for?
Wegovy HD is for adults with obesity, or overweight with a weight-related condition, who have tolerated Wegovy 2.4 mg for at least 4 weeks and need additional weight loss. It is not approved for teenagers. Your doctor will determine if it is appropriate for you.
How much more weight can you lose on Wegovy HD vs standard Wegovy?
In the 72-week STEP UP trial in adults with obesity without diabetes, average weight loss was 20.7% with 7.2 mg among people who stayed on treatment (18.7% counting everyone), compared with about 15.6% with 2.4 mg (counting everyone). About 1 in 3 (31.2%) on 7.2 mg lost 25% or more.
Is Wegovy HD the same injection as regular Wegovy?
It is the same medicine (semaglutide) given as a weekly injection under the skin, at a higher dose. In the US, Wegovy HD comes as a 7.2 mg single-dose pen, so the pen you use may differ from your previous one.
How do you escalate to the Wegovy HD 7.2 mg dose?
You would not start directly at 7.2 mg. You first go through the standard Wegovy dose steps up to 2.4 mg. Under the US label, if you have tolerated 2.4 mg for at least 4 weeks and your doctor decides more weight loss is needed, the dose may be increased to 7.2 mg once weekly. Your doctor decides whether and when.
Will Wegovy HD be covered by insurance?
Coverage is determined by your individual insurance plan. Plans that cover Wegovy may or may not cover the 7.2 mg dose in the same way. Contact your insurer directly to confirm.
How does Wegovy HD compare to Zepbound or Mounjaro?
In SURMOUNT-1, Zepbound 15 mg produced an average of 20.9% weight loss at 72 weeks (counting everyone). In STEP UP, Wegovy 7.2 mg produced 18.7% (counting everyone) or 20.7% among people who stayed on treatment. These were separate trials, so they cannot be compared directly, and the two have not been tested head to head. Tirzepatide targets both GLP-1 and GIP receptors, while Wegovy HD is a higher dose of semaglutide.
Written by
Masters in Microbiology
Health Content Writer
Anuja Akkar is a Masters in Microbiology professional who contributes evidence-informed health and wellness content for Weight Easy.
View profile →Reviewed by
BHMS
Senior Medical Reviewer
Dietitian with experience in nutrition counseling, meal planning and promoting healthy lifestyles. Dedicated to help individuals achieve optimal health and well-being through personalized nutrition strategies. Skilled in providing expert guidance for managing conditions like diabetes, weight challenges and Lifestyle management.
View profile →